Objective: Cut homeodomain transcription factor CUX2 plays an important role in dendrite branching, spine development, and synapse formation in layer II to III neurons of the cerebral cortex. We identify a recurrent de novo CUX2 p.Glu590Lys as a novel genetic cause for developmental and epileptic encephalopathy (DEE). Methods: The de novo p.Glu590Lys variant was identified by whole-exome sequencing (n 5 5) or targeted gene panel (n 5 4). We performed electroclinical and imaging phenotyping on all patients. Results: The cohort comprised 7 males and 2 females. Mean age at study was 13 years (0.5-21.0). Median age at seizure onset was 6 months (2 months to 9 years). Seizure types at onset were myoclonic, atypical absence with myoclonic components, and focal seizures. Epileptiform activity on electroencephalogram was seen in 8 cases: generalized polyspike-wave (6) or multifocal discharges (2). Seizures were drug resistant in 7 or controlled with View this article online at wileyonlinelibrary.com.
valproate (2) . Six patients had a DEE: myoclonic DEE (3), Lennox-Gastaut syndrome (2) , and West syndrome (1) . Two had a static encephalopathy and genetic generalized epilepsy, including absence epilepsy in 1. One infant had multifocal epilepsy. Eight had severe cognitive impairment, with autistic features in 6. The p.Glu590Lys variant affects a highly conserved glutamine residue in the CUT domain predicted to interfere with CUX2 binding to DNA targets during neuronal development. Interpretation: Patients with CUX2 p.Glu590Lys display a distinctive phenotypic spectrum, which is predominantly generalized epilepsy, with infantile-onset myoclonic DEE at the severe end and generalized epilepsy with severe static developmental encephalopathy at the milder end of the spectrum. ANN NEUROL 2018; 83:926-934 D evelopmental and epileptic encephalopathies (DEEs) are a group of severe infantile and childhood onset epilepsies characterized by developmental slowing or regression in the context of recurrent seizures and frequent interictal epileptiform discharges, often on a background of developmental delay. 1 DEEs have a wide range of etiologies, including both acquired and genetic causes. Considerable genetic heterogeneity has been demonstrated by recent advances in molecular genetics and next-generation sequencing (NGS), with more than 100 genes implicated, with various modes of inheritance. Identification of the pathogenic variant ends the diagnostic odyssey for patients and their families, provides information regarding prognosis and comorbidities, and informs accurate genetic counseling. In addition, the identification of patients with a genetically defined epilepsy can allow therapeutic management to be optimized and pave the way to novel targeted approaches. 2 Pathogenic variants in a subset of genes account for a significant proportion of patients with DEEs, such as SCN1A, SCN2A, SCN8A, KCNQ2, STXBP1, and CDKL5, whereas many other genetic causes are rare. 3 For these rare genetic disorders, the small number of patients with pathogenic variants in single genes often requires international collaborations to identify multiple cases to facilitate careful delineation of the phenotype. 4 The de novo c.1768G>A (p.Glu590Lys) missense variant in CUX2 (NM_015267.3) was first reported in single cases from two large-scale whole-exome sequencing (WES) studies: one from a study of intellectual disability and the other a cohort of two specific DEEs, infantile spasms and Lennox-Gastaut syndrome. 5, 6 In this article, we describe 7 additional patients with the same recurrent p.Glu590Lys missense variant in CUX2, shown to be de novo in all cases. We present the clinical data for these 9 patients and describe the phenotypic spectrum associated with this new recurrent genetic disorder, which most frequently presents as a severe developmental and epileptic encephalopathy.
Patients and Methods
This study was approved by the institutional review boards of the participating institutions. Informed consent was provided by the parent or patient's legal guardian because all patients were minors or had intellectual disability. CUX2 variants were identified by WES (n 5 2) or targeted gene panel sequencing (n 5 5), using previously described methods, 7, 8 and were collated through the Matchmaker Exchange network 4 or personal communication with colleagues. We analyzed the clinical phenotype for the 7 new patients as well as the 2 individuals previously reported on. 5, 6 Seizure onset age, seizure types, electroencephalogram (EEG), and neuroimaging findings were obtained, together with a history of each patient's developmental course. Three-dimensional (3D) modeling of structural effects was performed using either the mutate_model script in MOD-ELLER 9 or using the available solution structure for residues 544 to 631 (PDB 1X2L) for the CUT1 domain of CUX2. The resulting models were visualized using the SWISS-PdbViewer. 10 The same 1X2L PDB file was also used as input for protein stability prediction applications: CUPSAT, 11 I-mutant3.0, 12 SNPs&GO 3d . 13 The web servers HOPE 14 or PHYRE2 15 were also used for in silico prediction of pathogenic variant effects on protein function. Multiple protein sequence alignments were done on Clustal Omega at EMBL-EBI server. 16 
Results

Identification of Patients With the p.Glu590Lys
Variant NGS identified a heterozygous de novo variant: Chr12:111748354G>A (hg19), c.1768G>A transition in CUX2 in all 7 patients. The c.1768G>A is predicted to lead to a substitution of the glutamate residue, p. Glu590Lys. This variant has not been reported in the ExAC/gnomAD databases. Taken together with the two previously published cases, 2 individuals were identified through clinical diagnostic testing, 3 of 1,222 through research studies in patients with DEE, and 4 of 2,207 individuals were identified by screening of patient cohorts with intellectual disability with/without epilepsy.
Phenotype of Patients With the CUX2
Glu590Lys Variant
Seven patients were male and 2 were female. Median age at study inclusion was 13 years (0.5-21.0; Table 1 ). Six of the 9 patients had a DEE, whereas 2 presented with a severe, static, developmental encephalopathy with genetic generalized epilepsy (GGE). Their GGE comprised absence seizures in 1 (patient 9) and early-onset absence epilepsy and myoclonic seizures in the other (patient 5). Patient 8 had focal epilepsy, but, because he is only 6 months old, he is too young to predict his developmental outcome ( Table 1 ). The pregnancy and perinatal period were unremarkable in all patients. Median age at seizure onset was 6 months (range, 2 months to 9 years). Seizure types at onset were myoclonic (n 5 4), absence (n 5 2), atypical absence with myoclonic components (2), and focal (n 5 3), including occipital (1), hemiclonic (1), and focal epileptic spasms (1). Generalized tonic-clonic seizures only occurred in 1 child at presentation. Apnea occurred with occipital seizures in 1 infant and with atypical absence seizures in another. Seizures were frequent at onset with multiple seizures per day. EEG was abnormal at seizure onset in all individuals, most frequently showing generalized spike-wave or polyspike-wave (n 5 5; Table 2 ). Focal features were also noted, including temporal discharges (n 5 1), occipital discharges (n 5 1), multifocal discharges (n 5 1), hypsarrhythmia (n 5 1), and focal slowing (n 5 1).
Valproate fully controlled seizures in 2 patients (Table 3) . In patient 5, absence seizures were initially well controlled on valproate until an episode of nonconvulsive status epilepticus at age 3 years, with rare episodes occurring every few years. The remaining 5 patients were refractory to multiple antiepileptic drugs (AEDs), including valproate. With the evolution of their epilepsy, multiple seizure types often emerged, including myoclonic seizures (n 5 5), absence (n 5 5), and generalized tonic-clonic seizures (n 5 5).
EEG studies at follow-up showed variable features, including generalized spike-wave (GSW) (5), focal or multifocal discharges (2), and background slowing (5) ( Table 2 ). The EEG was normal in patient 9, who was seizure free. Myoclonic seizures were recorded with GSW or GPSW.
Seven of the 9 patients had severe intellectual disability and were nonverbal; 1 had profound impairment ( Table 3 ). The remaining patient is currently 6 months old, so his outcome is unclear. Seven patients could walk. Patients 2 and 4 experienced marked developmental regression during childhood, not related to frequent seizures or epileptiform activity. Two patients had autistic features. Movement disorders were observed in 5 cases, often comprising stereotypies such as hand flapping, dyskinesia, or athetosis. In 3 patients, inappropriate episodes of laughter were observed; these episodes did not have an EEG correlate in 2 individuals and were not thought to be epileptic in origin. Brain magnetic resonance imaging (MRI) was normal in 6 of 9 individuals; findings in the remaining 3 patients showed cerebellar atrophy (1), hippocampal asymmetry (n 5 1), and a thin corpus callosum (n 5 1). In Silico Analysis of the p.Glu590Lys Pathogenic Variant The p.Glu590Lys missense variant is located within the third alpha helix of the first DNA-binding CUT domain (IPR003350; Fig 1A) . This residue is highly conserved among orthologues (Fig 1B) . Moreover, the negative charge at this residue seems particularly important, given that it is conserved among all CUT domains, and up to the homologous domain Cro/C1-type helix-turn-helix domain (IPR001387) from Repressor protein cI of bacteriophages lambda (Fig 1C) . This variant was predicted to be damaging by several computational tools (SIFT 5 0.001, Polyphen-2 5 1, fathmm-MKL_coding_score 5 0.985, and CADD 5 33.0). Additionally, the SNPs&GO 3d tool, which combines structural information from the 1X2L crystal structure and Gene Ontology terms, classified the variant as disease associated.
Computational modeling using the available crystal structure for the first CUT domain (1X2L) suggested that the substitution causes no major change in the alpha helix (Fig 2A) . The conformation of the CUT1 domain of CUX2 relative to the DNA is not yet known. However, the CUT1 domain of human homeobox protein CUX2 (1X2L) has been crystalized. Also, the rat HNF6a CUT and Homeobox domains (2D5V) have been crystalized along with the DNA sequence of a specific promoter. The E54 residue (1X2L) and D41 residue (2D5V), homologues of the Glu590, are located in the middle of the third helix (Fig 2B) , directly facing the major groove of the DNA helix (Fig 2C) . Analysis using the HOPE prediction tool showed that salt bridges are normally formed between amino acid positions 594 and 596 that will be disrupted by the pathogenic variant. The lysine residue is also larger and is positively charged, whereas wild-type glutamine has a negative charge. Calculations of protein stability using various prediction tools suggested that this substitution could lead to destabilization of CUX2 (CUPSAT: DDG 5 -0.17 kcal/ mol; I-mutant3.0: DDG 5 -0.85 kcal/mol).
Discussion
In this study, we describe a recurrent de novo missense variant p.Glu590Lys in CUX2 as a novel cause for DEE in the majority of patients. All patients carry the same recurrent missense variant, suggesting an important role for this residue in CUX2 function. Based on the ExAC data set, CUX2 is generally intolerant to variation; the probability of loss-of-function intolerance score is very high (pLI 5 1), as it is for missense variants (Z-score 5 3.61). 17 Because the same pathogenic variant has occurred independently in 9 patients, and that CUX2 is intolerant to genetic variation, we hypothesize that this amino acid position plays a specific role in the pathophysiological process. The predominant phenotype was an infantile-onset myoclonic DEE with a phenotypic DEE spectrum that extended to Lennox-Gastaut syndrome and infantile spasms, as well as a static developmental encephalopathy with genetic generalized epilepsy.
Infantile onset of seizures was usual with a median onset of 6 months. Myoclonic seizures or absence seizures with a myoclonic component were the most frequent type of seizures at onset (5 of 9). Absence seizures were also prominent, especially in the 2 cases with developmental encephalopathy, who did not have evidence for an epileptic encephalopathy. This is distinguished by developmental delay leading to intellectual disability, without plateauing or regression of development, and associated with epilepsy. 1 One had episodes of nonconvulsive status epilepticus, but these were rare and not associated with developmental slowing; however, it does suggest a more severe form of absence epilepsy, as can be observed in early-onset absence epilepsy (defined as onset under 4 years). In general, seizures were refractory to multiple AEDs, although 2 cases were seizure free on valproate. Additional seizure types often evolved and included atypical absences, tonic, and generalized tonic-clonic seizures. Focal seizures were rare.
The majority of patients with the p.Glu590Lys recurrent de novo variant had severe to profound intellectual disability, with developmental regression observed in 2 cases. The majority were nonverbal but could walk. Additional features included movement disorders with stereotypies such as hand flapping and dyskinesia, autistic features, and inappropriate nonepileptic laughing episodes. This severe cognitive impairment is attributed to a developmental component, together with a superimposed epileptic encephalopathy in those with a DEE. This developmental component is illustrated by early developmental delay in some cases, preceding seizure onset, and by the 2 individuals with severe ID without a DEE.
Cux2 and its orthologue, Cux1, encode the vertebrate homologs of the Drosophila homeobox DNAbinding transcription factor, Cut. 19, 20 Despite their divergent evolution, Cux1 and Cux2 exhibit high sequence conservation within specific protein regions, notably the Cut repeat domains. Whereas Cux1 is expressed in most tissues, Cux2 is expressed primarily in neuronal tissues during development and continues to be expressed in postmitotic neurons, where it is a marker of the upper layer II to III neurons. 21 Cux2 -/-knockout mice had normal cortical organization. Similar to these findings, there were no obvious structural or organizational abnormalities in the majority of patients given that brain MRI was normal or showed mild nonspecific features (n 5 3). However, Cux2 -/-knockout mice displayed decreased dendritic length as well as reduction in the number of branches, density of spines, and synaptic function in the layer II to III neurons. 22, 23 These abnormal dendrites and synapses in Cux2 -/-mice correlate with reduced synaptic function and defects in working memory, though seizures were not reported. 24 The intellectual disability phenotypes observed in patients may be related to putative abnormal dendritic branching or function, especially in layer II to III neurons of brain cortex, as observed in Cux2 knockout mice. The CUX2 p.Glu590Lys pathogenic variant is located in the first alpha helix of the CUT domain 1 (CR1). This protein domain plays an important role in the binding of CUX2 to its DNA targets, where it controls gene expression as a transcription factor. Our in silico analyses point toward a destabilization effect in the presence of the mutant lysine residue. This change to a highly conserved positive charge (lysine) could therefore alter the interaction with the negatively charged DNA's phosphate backbone. Interestingly, no loss-of-function (truncating) variants have been observed in patients nor controls, suggesting that complete loss of CUX2 function may be lethal. Collectively, these results suggest that the p.Glu590Lys pathogenic variant alters either the stability or specificity of the interaction of CUX2 with the DNA, which is known to be transient. 25 This may confer a partial loss of function effect for the p.Glu590Lys variant. Alternatively, another possibility is that this variant confers gain of function or dominant negative properties, in which the mutant protein has an inhibitory interaction on the normal allele, or binds ectopic target DNA regions. In order to determine the functional effect of this missense variant, functional studies in CUX2 knockout and the CUX2 p.Glu590Lys variant in vitro and in vivo need to be performed. Our study highlights the importance of international collaborative efforts to identify novel genes implicated in epilepsy, which are likely to be rare overall and thus require large cohorts of patients to identify recurrent mutations in genes. Moreover, until now, novel gene discovery in epilepsy has largely focused on truncating variants, partly because these variants are easier to interpret in the context of a haploinsufficient model. However, in accord with a recent study that included molecular data from patients 6 and 9, the present study emphasizes the importance of recurrent missense variation in neurodevelopmental disorders, including intellectual disability and epilepsy. 26 This observation has also been illustrated in the epilepsies in a recent study that identified a recurrent missense mutation in a more common epilepsy gene, SCN1A, that produced a profound phenotype, far more severe than the well-established Dravet syndrome presentation of this gene. 7 In addition, the role of missense mutations in DEE, and especially recurrent ones, has been emphasized in another recent article. 27 The study of recurrent pathogenic missense variation provides a unique avenue to understand the role of a protein (and its domains) in neuronal development and function. Future functional studies will be important to understand the pathophysiological process of this specific CUX2 pathogenic variant, but also the function of CUX2.
